Research programme: antiviral nucleotides - Alios BioPharma

Drug Profile

Research programme: antiviral nucleotides - Alios BioPharma

Alternative Names: AL-516; Guanosine analogue - Alios BioPharma

Latest Information Update: 10 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alios BioPharma
  • Class Nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 07 Nov 2014 Alios BioPharma has been acquired by Johnson & Johnson
  • 06 Nov 2014 Antimicrobial data from a preclinical trial in Hepatitis C virus were released by Alios BioPharma
  • 15 Sep 2014 Preclinical trials in Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top